Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Crosses Below Two Hundred Day Moving Average – Time to Sell?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)’s share price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $13.75 and traded as low as $10.86. Enanta Pharmaceuticals shares last traded at $11.07, with a volume of 158,110 shares trading hands.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on ENTA shares. Wall Street Zen cut shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 10th. Rodman & Renshaw started coverage on shares of Enanta Pharmaceuticals in a research note on Thursday, March 26th. They issued a “buy” rating and a $20.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Monday, April 20th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $20.29.

Enanta Pharmaceuticals Stock Up 3.1%

The stock has a market capitalization of $340.24 million, a price-to-earnings ratio of -4.52 and a beta of 0.97. The stock’s 50-day simple moving average is $13.48 and its 200 day simple moving average is $13.74.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, May 11th. The biotechnology company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.01. The firm had revenue of $17.16 million for the quarter, compared to analyst estimates of $17.03 million. Enanta Pharmaceuticals had a negative net margin of 89.56% and a negative return on equity of 64.04%. As a group, equities research analysts anticipate that Enanta Pharmaceuticals, Inc. will post -1.79 earnings per share for the current year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ENTA. Janus Henderson Group PLC boosted its position in Enanta Pharmaceuticals by 91.6% in the fourth quarter. Janus Henderson Group PLC now owns 3,729,659 shares of the biotechnology company’s stock valued at $58,761,000 after buying an additional 1,782,745 shares in the last quarter. Commodore Capital LP acquired a new position in Enanta Pharmaceuticals in the third quarter valued at about $9,576,000. Krensavage Asset Management LLC boosted its position in Enanta Pharmaceuticals by 30.8% in the fourth quarter. Krensavage Asset Management LLC now owns 2,766,390 shares of the biotechnology company’s stock valued at $43,626,000 after buying an additional 651,946 shares in the last quarter. Farallon Capital Management LLC boosted its position in Enanta Pharmaceuticals by 30.6% in the fourth quarter. Farallon Capital Management LLC now owns 2,772,262 shares of the biotechnology company’s stock valued at $43,719,000 after buying an additional 650,000 shares in the last quarter. Finally, Spruce Street Capital LP boosted its position in Enanta Pharmaceuticals by 139.3% in the first quarter. Spruce Street Capital LP now owns 932,598 shares of the biotechnology company’s stock valued at $11,779,000 after buying an additional 542,911 shares in the last quarter. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.